½ÃÀ庸°í¼­
»óǰÄÚµå
1516093

¼¼°èÀÇ AI ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü ½ÃÀå : Á¦Ç°º°, À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ¿¹Ãø(2024-2032³â)

Cardiac AI Monitoring and Diagnostics Market, By Product (Hardware, Software Solutions, Services), Type (Cardiac Diagnostics, Monitoring), Application (Cardiac Arrhythmias, Stroke, Ischemic Heart Disease, Stenosis), End-use & Forecast, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è AI ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü ½ÃÀå ±Ô¸ð´Â °í·ÉÈ­¿Í ½ÉÇ÷°ü Áúȯ(CVDs) À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î 2024-2032³â ¿¬Æò±Õ 26.9% ÀÌ»ó ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

WHO¿¡ µû¸£¸é, ½ÉÇ÷°ü Áúȯ(CVDs)Àº Àü ¼¼°èÀûÀ¸·Î ¿¬°£ ¾à 1,790¸¸ ¸íÀÌ »ç¸ÁÇÏ´Â ÁÖ¿ä »ç¸Á ¿øÀÎÀÔ´Ï´Ù.

CVD°¡ ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ¶°¿À¸£¸é¼­ Á¶±â ¹ß°ß°ú °ü¸®¸¦ À§ÇÑ È¿°úÀûÀÎ Áø´Ü µµ±¸°¡ ÇÊ¿äÇϸç, AI´Â º¹ÀâÇÑ ½ÉÀå µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î Á¤È®ÇÏ°Ô ºÐ¼®ÇÏ¿© Á¶±â Áø´ÜÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á ±âÁ¸ Áø´Ü ¹æ¹ýº¸´Ù ÈξÀ ´õ ³ªÀº °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. AI¿Í ¿þ¾î·¯ºí ±â±â ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼ú°úÀÇ ÅëÇÕÀ» ÅëÇØ ½ÉÀå °Ç°­ »óŸ¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ÀÌ´Â Àû½Ã¿¡ °³ÀÔÇϰí ȯÀÚ ¸ÂÃãÇü Ä¡·á¸¦ À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ¿Í Á¤ºÎÀÇ Áö¿ø Á¤Ã¥Àº ÀÇ·á ¿¬±¸ ºÐ¾ß¿¡¼­ AIÀÇ Ã¤ÅÃÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ½ÉÀå ¸ð´ÏÅ͸µ¿¡¼­ AI ±â¹Ý ¼Ö·ç¼ÇÀÇ È°¿ëÀº ºòµ¥ÀÌÅÍÀÇ °¡¿ë¼º Áõ°¡¿Í ½Ã½ºÅÛÀÇ ¿¹Ãø Á¤È®µµ¿Í È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â ML ¾Ë°í¸®ÁòÀÇ ¹ßÀü¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î AI ¼Ö·ç¼ÇÀ» °³¹ß ¹× ¹èÆ÷Çϱâ À§ÇÑ ÇÏÀÌÅ×Å© ±â¾÷ ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ ÆÄÆ®³Ê½Êµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

AI ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü »ê¾÷Àº Á¦Ç°, À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°À» ±â¹ÝÀ¸·Î ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼Ç ºÎ¹®ÀÇ ½ÃÀå ±Ô¸ð´Â ½ÉÀå Áø´ÜÀÇ Á¤È®¼º, À¯È¿¼º ¹× ¹üÀ§¸¦ È®ÀåÇÏ´Â °í±Þ ¾Ë°í¸®Áò°ú ML ¸ðµ¨À» Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ 2032³â±îÁö °­·ÂÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀº ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®, ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿¹Ãø ºÐ¼®À» ÅëÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ ȯÀÚÀÇ ½ÉÀå °Ç°­ »óŸ¦ ÀüüÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÓ»ó ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ »ç¿ëÇϱ⠽¬¿î ÀÎÅÍÆäÀ̽º¿Í ÀÇ·á±â±â ¹× ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ½Ã½ºÅÛ°úÀÇ »óÈ£ ¿î¿ë¼ºÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

AI ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü ½ÃÀåÀº ½ÉÀå °Ç°­ »óŸ¦ Áö¼ÓÀûÀ¸·Î ½Ç½Ã°£À¸·Î ÃßÀûÇØ¾ß ÇÏ´Â Çʿ伺À¸·Î ÀÎÇØ ½ÉÀå ¸ð´ÏÅ͸µ À¯Çü ºÎ¹®¿¡¼­ 2024-2032³â »çÀÌ »ó´çÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½º¸¶Æ® ¿þ¾î·¯ºí ¹× ÀÓÇöõÆ® ¼¾¼­¿Í °°Àº AI ±â¹Ý ½ÉÀå ¸ð´ÏÅ͸µ ±â±â´Â ½ÉÀå ¸®µë, Ç÷¾Ð ¹× ±âŸ Áß¿äÇÑ ¸Å°³ º¯¼ö¿¡ ´ëÇÑ Á¤È®ÇÏ°í ºü¸¥ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ½ÉÀå ¸ð´ÏÅ͸µ¿¡ AI¸¦ ÅëÇÕÇÏ¸é ¸¸¼º ½ÉºÎÀü °ü¸®¸¦ °³¼±ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ÀæÀº º´¿ø ¹æ¹®ÀÇ Çʿ伺À» ÁÙÀ̸鼭 ȯÀÚÀÇ ¿ø°Ý ¸ð´ÏÅ͸µÀ» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ AI ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü »ê¾÷Àº 2024-2032³â µ¿¾È Áö¼ÓÀûÀÎ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, µµ½ÃÈ­, °í·ÉÈ­·Î ÀÎÇØ ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. Áß±¹, Àεµ, ÀϺ»¿¡¼­ÀÇ µðÁöÅÐ Çコ ±â¼úÀÇ ±Þ¼ÓÇÑ Ã¤Åðú ÀÇ·á ¼­ºñ½ºÀÇ °³¼±Àº ½ÉÇ÷°ü Áúȯ¿¡ AIÀÇ ÅëÇÕÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ³ë·Â°ú ÇコÄɾî Çõ½Å¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ´Â ÀÌ Áö¿ª¿¡¼­ AI ±â¹Ý ½ÉÀå ¸ð´ÏÅ͸µ ¹× Áø´Ü µµ±¸ÀÇ °³¹ß°ú Áø´ÜÀ» ´õ¿í Áö¿øÇÒ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ½ÉÇ÷°üÁúȯ À¯º´·ü »ó½Â
      • ¿ø°Ý °¨½Ã ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä »ó½Â
      • ±â¼úÀÇ Áøº¸
      • Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñ »ó½Â
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ©¡¤°úÁ¦
      • ³ôÀº µµÀÔ ºñ¿ë
      • ÇÑÁ¤µÈ »óÈ£¿î¿ë¼º°ú ÅëÇÕ¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼úÀû Àü¸Á
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï »óȲ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Á¦Ç°º°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Çϵå¿þ¾î
  • ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼Ç
  • ¼­ºñ½º

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ½ÉÀå Áø´Ü
    • ¿µ»ó Áø´Ü
    • ECG ±â¹Ý
    • ±âŸ Áø´Ü ±â¼ú
  • ½ÉÀå ¸ð´ÏÅ͸µ

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÎÁ¤¸Æ
  • ³úÁ¹Áß
  • ÇãÇ÷¼º ½ÉÁúȯ
  • ÇùÂø
  • ±âŸ ¿ëµµ

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • Áø´Ü ¼¾ÅÍ
  • ¿¬±¸¡¤Çмú±â°ü
  • ±âŸ ÃÖÁ¾ ¿ëµµ

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • CardiAI
  • Cleerly, Inc.
  • DiA Imaging Analysis
  • HeartVista Inc.
  • IDOVEN
  • Koninklijke Philips N.V.
  • RSIP Vision
  • Tempus
  • Ultrasight
  • Ultromics Limited
  • Viz.ai, Inc.
ksm 24.07.30

Cardiac AI monitoring and diagnostics market is estimated to record over 26.9% CAGR during 2024-2032, driven by the increasing prevalence of cardiovascular diseases (CVDs), coupled with the aging population. As per WHO, cardiovascular diseases (CVDs) are the leading cause of mortality, with an estimated 17.9 million deaths per year worldwide.

With CVDs emerging as the major cause of morbidity and mortality, effective diagnostic tools are needed for early detection and management. AI offers significant improvements over traditional diagnostic methods for providing accurate, real-time analysis of complex cardiac data while allowing early and accurate diagnosis. The integration of AI with wearable devices and remote monitoring techniques is also enabling continuous monitoring of heart health, which is important for timely interventions and personalized patient care.

Major investments in health technology and supportive government policies will encourage the adoption of AI in medical research. The use of AI-driven solutions in cardiac monitoring relies on the growing availability of big data and advancements in ML algorithms to increase the predictive accuracy and efficiency of the systems. Partnerships between tech companies and healthcare providers to develop and deploy new AI solutions are also driving the market growth.

The cardiac AI monitoring and diagnostics industry is segmented into product, type, application, end-use and region.

Based on product, the market size from the software solutions segment is slated to record strong CAGR through 2032 due to its ability to provide advanced algorithms and ML models that increase the accuracy, efficacy, and scope of cardiac diagnosis. This software solution enables real-time data analytics, remote monitoring, and predictive analytics while giving healthcare providers a holistic view of the patient's cardiac health. Easy-to-use interfaces and interoperability with medical devices and electronic health record (EHR) systems to streamline clinical workflow and improve patient outcomes will add to the segment growth.

Cardiac AI monitoring and diagnostics market from the cardiac monitoring type segment is projected to observe substantial CAGR between 2024 and 2032, owing to the need for continuous and real-time tracking of heart health. AI-powered heart monitoring devices, such as smart wearables and implantable sensors, provide accurate and rapid insights into heart rhythms, blood pressure and other vital parameters. The integration of AI into cardiac monitoring facilitates the remote monitoring of patients while reducing the need for frequent hospital visits as well as improving the management of chronic heart failure.

Asia Pacific cardiac AI monitoring and diagnostics industry will witness sustained growth rate between 2024 and 2032. This is attributed to the increasing burden of cardiovascular diseases, driven by lifestyle changes, urbanization, and aging population. The rapid adoption of digital health technologies and improvements in healthcare in China, India and Japan are facilitating the integration of AI into cardiology. Government initiatives and large investments in healthcare innovation will further support the development and AI-powered cardiac monitoring and diagnostic tools in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cardiovascular diseases
      • 3.2.1.2 Growing demand for remote monitoring solutions
      • 3.2.1.3 Technological advancements
      • 3.2.1.4 Increasing focus on precision medicine
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High implementation costs
      • 3.2.2.2 Limited interoperability and integration
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hardware
  • 5.3 Software solutions
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cardiac diagnostics
    • 6.2.1 Imaging
    • 6.2.2 ECG-based
    • 6.2.3 Other diagnostic techniques
  • 6.3 Cardiac monitoring

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cardiac arrhythmias
  • 7.3 Stroke
  • 7.4 Ischemic heart disease
  • 7.5 Stenosis
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Diagnostic centers
  • 8.5 Research and academic institutes
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 CardiAI
  • 10.2 Cleerly, Inc.
  • 10.3 DiA Imaging Analysis
  • 10.4 HeartVista Inc.
  • 10.5 IDOVEN
  • 10.6 Koninklijke Philips N.V.
  • 10.7 RSIP Vision
  • 10.8 Tempus
  • 10.9 Ultrasight
  • 10.10 Ultromics Limited
  • 10.11 Viz.ai, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦